patient

Section snippets Background Myelodysplastic neoplasms (MDS) are a heterogenous group of hematopoietic stem cell malignancies characterized by ineffective hematopoiesis and tendency to progress to acute myeloid leukemia (AML).1 Patients (pts) are risk stratified to tailor…

Abstract Outcomes for acute myeloid leukemia (AML) have improved significantly in the past decade with the approval of novel therapeutics targeting diverse vulnerabilities of leukemic cells, expanded access to stem cell transplantation, and improved safety of transplantation…

ABSTRACT Patients with TP53 mutations in acute myeloid leukemia (AML) and blast phase myeloproliferative neoplasms (MPN-BP) experience similar poor clinical outcomes. A retrospective analysis of 39 patients with TP53 mutations (23 with AML and 16 with MPN-BP) revealed comparable…

Dear Editor, Secondary acute myeloid leukemia (sAML), a subset of AML, may arise from antecedent hematologic disorders (antecedent myelodysplastic syndrome or chronic myelomonocytic leukemia [A-MDS/CMML]) or complication of prior cytotoxic chemotherapy or radiation therapy…

To the Editor, Core-binding factor acute myeloid leukemia (CBF-AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and is classified as favorable risk by the 2022 European LeukemiaNet (ELN) guidelines [1]. We have previously reported on outcomes of patients with…

Abstract Context.—: Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.—: To propose a standardized approach to MDS evaluation in bone marrow specimens by (1)…